Pharmaceuticals 2014, 7(7), 765-778; doi:10.3390/ph7070765
Review

Imaging Biomarkers or Biomarker Imaging?

email and * email
Received: 9 January 2014; in revised form: 13 June 2014 / Accepted: 17 June 2014 / Published: 25 June 2014
(This article belongs to the Special Issue Radiopharmaceutical Chemistry between Imaging and Radioendotherapy)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Since biomarker imaging is traditionally understood as imaging of molecular probes, we highly recommend to avoid any confusion with the previously defined term “imaging biomarkers” and, therefore, only use “molecular probe imaging (MPI)” in that context. Molecular probes (MPs) comprise all kinds of molecules administered to an organism which inherently carry a signalling moiety. This review highlights the basic concepts and differences of molecular probe imaging using specific biomarkers. In particular, PET radiopharmaceuticals are discussed in more detail. Specific radiochemical and radiopharmacological aspects as well as some legal issues are presented.
Keywords: tracer; molecular probe; PET; radiopharmaceutical
PDF Full-text Download PDF Full-Text [1366 KB, uploaded 25 June 2014 13:39 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Mitterhauser, M.; Wadsak, W. Imaging Biomarkers or Biomarker Imaging? Pharmaceuticals 2014, 7, 765-778.

AMA Style

Mitterhauser M, Wadsak W. Imaging Biomarkers or Biomarker Imaging? Pharmaceuticals. 2014; 7(7):765-778.

Chicago/Turabian Style

Mitterhauser, Markus; Wadsak, Wolfgang. 2014. "Imaging Biomarkers or Biomarker Imaging?" Pharmaceuticals 7, no. 7: 765-778.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert